A “tailored” interventional and surgical management for moderate to critical acute pancreatitis in late phase: a cohort study

Purpose Several interventional procedures are available to treat moderate-to-critical acute pancreatitis (AP) in its late phase. The ongoing debate on these options, together with the scarcity of reported quality of life (QoL) information in the Literature, prompted us to conduct a review of our experience. Methods All the patients treated at our referral Center for moderate-to-critical AP according to Determinant-Based Classification (DBC) were retrospectively reviewed. Patients treated conservatively or operated within 4 weeks were excluded. The included patients were managed following a “tailored” interventional-surgical approach, which did not exclude the possibility to skip one or more steps of the classic “step-up” approach, based on the patient’s clinical course, and divided into four groups, according to the first procedure performed: percutaneous drainage (PD), endoscopic approach (END), internal derivation (INT), and necrosectomy (NE). In-hospital and mid-term follow-up variables were analyzed. Results The study sample consisted in 47 patients: 11 patients were treated by PD, 11 by END, 13 by INT, and 12 by NE. A significant distribution of the DBC severity ( p = 0.029) was registered among the four groups. Moreover, the NE group had statistically significant reduced SF-36 scores in the domain of social functioning at 3 months ( p = 0.011), at 1 year ( p = 0.002), and at 2 years ( p = 0.001); role limitations due to physical health at 6 months ( p = 0.027); and role limitations due to emotional problems at 1 year ( p = 0.020). Conclusions In the “late phase” of moderate to critical AP requiring an invasive management, PD, END, INT, and NE are all effective options, depending on patents’ status and necrosis location. A “tailored” interventional-surgical management could be pursued, but up-front more invasive approaches are at higher risk of worse QoL. Trial registration. The manuscript was registered at clinicaltrials.gov in 04/2021 and identified with NCT04870268.